: Tiankang: Wholly-owned subsidiary received registration certificate for piracetam tablets.

Tienkang announcement, its wholly-owned subsidiary Anhui Tienkang Pharmaceutical Co., Ltd recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the drug Perampanel tablets. Perampanel is a highly selective, non-competitive AMPA receptor antagonist that works by inhibiting the activity of glutamate on post-synaptic AMPA receptors, reducing neuronal excitability, and is used for the prevention and treatment of epilepsy. It is approved for adjunctive treatment of partial-onset seizures in adults and patients aged 12 and older.